|Bid||36.70 x 900|
|Ask||36.71 x 800|
|Day's Range||36.35 - 37.04|
|52 Week Range||24.54 - 39.44|
|Beta (3Y Monthly)||1.00|
|PE Ratio (TTM)||96.83|
|Earnings Date||Oct 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.50|
When the stock market dips, prudent investors make a shopping list of stocks to buy. • The chart shows the support zone. • Regarding long-term thinking, it is better to think in terms of a support zone and support levels within that zone.
How Is Medtronic Positioned in October? On October 12, Medtronic stock closed at $94.69, which is a ~1.7% rise from its prior-day close of $93.11 on October 11 and a ~24% rise from its 52-week low of $76.41. Medtronic hit its 52-week high of $100.15 on September 26, 2018.
One of the most overlooked $54 billion companies in the market is medical devices maker Boston Scientific, which is enjoying a great year. Most of the airline sector is boasting attractive valuations right now, and UAL stands out as it has shown great relative strength versus its peers this year.
Dow Jones futures: In a stock market correction, it's a good time to build a watch list. Check out Apple, UnitedHealth, Microsoft and other top stocks with strong relative strength.
Edwards Lifesciences (EW) will release its third-quarter earnings results on October 23. The company is expected to register adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
Edwards Lifesciences (EW) is scheduled to announce its third-quarter earnings results after the market closes on October 23. The company is a leading player in the artificial heart valve market.
Edwards Lifesciences (EW) is a leading transcatheter heart valve manufacturer in the United States. The company is set to release its third-quarter earnings results after the market closes on October 23. In this article, we’ll look at analysts’ recommendations and target prices for EW ahead of its third-quarter earnings release. According to an October 12 Reuters survey, which included 21 analysts covering EW stock, 62% of analysts (or 13) have recommended “buys” or “strong buys” on Edwards Lifesciences.
On October 17, before the market opens, Abbott Laboratories plans to announce its earnings results for the third quarter of 2018. Wall Street expects Abbott to register Q3 adjusted EPS (earnings per share) of $0.74, which would be a YoY (year-over-year) increase of 12.9%. In the second quarter, it reported adjusted EPS of $0.73, up 17.7% YoY, which exceeded analysts’ estimates.
Abbott Laboratories (ABT) plans to release its earnings results for its third quarter of 2018 on October 17 before the market opens. Wall Street expects its sales to be $7.65 billion, up 12% YoY (year-over-year).
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.
Abbott Laboratories (ABT) is slated to announce its Q3 earnings results on October 17. Let’s look at Wall Street analysts’ recommendations for ABT stock ahead of its earnings release.
Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.
During the investor update at the TCT (Transcatheter Cardiovascular Therapeutics) meeting on September 24, Boston Scientific increased its long-term outlook. For 2019 and 2020, it now expects operational sales growth of 7%–10%, which compares to the previous guidance of 6%–9%. It expects growth to be driven by both organic and inorganic growth.
On October 4, Boston Scientific (BSX) was trading at a forward PE ratio of 24.7x compared to the industry average of 22.9x. Let’s look at another key valuation multiple, the EV-to-EBITDA ratio, which is a capital structure–neutral valuation metric. Boston Scientific’s forward EV-to-EBITDA multiple is 19.4x, which is higher than the industry average of 17.3x.
Boston Scientific (BSX) stock traded at its 52-week high on October 2. It has seen tremendous growth momentum over the past year on the back of strong product launches, approvals, and acquisitions.
Boston Scientific Has Massive Bull Run: Is There More Upside? On October 3, Boston Scientific (BSX) stock closed at $38.61, a decline of ~1.1% compared to $39.04 on October 2. It hit a 52-week high of $39.44 during the day on October 2 when Morgan Stanely raised its target price.
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott Laboratories (ABT) offers market-leading products and solutions across its Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals operating segments.
Over the last six months, Boston Scientific (NYSE:BSX) has experienced an incredible rally. BSX stock has moved higher in 24 of the past 28 weeks, a streak that started back in March. As the weekly chart for BSX stock below shows the run and when it started.